New drug candidates for liposomal delivery identified b

Journal of Pharmaceutics & Drug Delivery Research .ISSN: 2325-9604

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

New drug candidates for liposomal delivery identified by computer modeling of liposomes remote loading and leakage

Amiram Goldblum

Hebrew University of Jerusalem, Israel
: J Pharm Drug Deliv Res


Remote drug loading into nano-liposomes is in most cases the best method for achieving high concentrations of active pharmaceutical ingredients (API) per nano-liposome that enable therapeutically viable API-loaded nano-liposomes, referred to as nano-drugs. This approach also enables controlled drug release. Recently, we constructed computational models to identify APIs that can achieve the desired high concentrations in nano-liposomes by remote loading. While those previous models included a broad spectrum of experimental conditions and dealt only with loading, here we reduced the scope to the molecular characteristics alone. We model and predict API suitability for nano-liposomal delivery by fixing the main experimental conditions: liposome lipid composition and size to be similar to those of Doxil® liposomes. On that basis, we add a prediction of drug leakage from the nano-liposomes during storage. The latter is critical for having pharmaceutically viable nano-drugs. The "load and leak" models were used to screen two large molecular databases in search of candidate APIs for delivery by nano-liposomes. The distribution of positive instances in both loading and leakage models was similar in the two databases screened. The screening process identified 667 molecules that were positives by both loading and leakage models (i.e., both high-loading and stable). Among them, 318 molecules received a high score in both properties and of these, 67 are FDA-approved drugs. This group of molecules, having diverse pharmacological activities, may be the basis for future liposomal drug development.


Amiram Goldblum is a Head of Molecular Modeling, Drug Design and Discovery Unit at Institute for Drug Research, Hebrew University. He completed his BSc in Chemistry and Physics and MSc in QM Studies of Molecular Spectra. He completed his PhD in Organic Reaction Mechanisms at Hebrew University followed by Post-doctoral studies in Quantum Biochemistry and QSAR and QM reaction mechanisms (California). He performed his research on “Protein reactions and interactions using semi-empirical QM and developed MNDO/H for dealing with H-bonding in relatively large molecular systems”. Since 2000, his group has been focusing on “Applications of his prize winning generic algorithm (ACS “emerging technologies”, Washington D.C. 2000) for finding sets of best solutions in extremely complex combinatorial problems. ISE (Iterative Stochastic Elimination) has been applied to protein structure and conformations, to protein-protein and protein-ligand interactions, to molecular properties and to the discovery of drug candidates.


Track Your Manuscript